Stoke Therapeutics, Inc. (NASDAQ: STOK)

Stoke Therapeutics, Inc., a clinical-stage biotechnology company, is at the forefront of addressing severe diseases by upregulating protein expression with RNA-based medicines. The company's TANGO (Targeted Augmentation of Nuclear Gene Output) approach employs antisense oligonucleotides (ASOs) to restore protein levels, offering a unique and innovative solution in the healthcare industry.

Stoke's primary business activities revolve around developing precision medicines for specific patient populations with genetic diseases. The company's focus is on genetic disorders of the central nervous system (CNS) and the eye, with the lead program, STK-001, targeting Dravet syndrome, a severe and progressive genetic epilepsy. Stoke's operations span across various countries and regions, with a strong presence in the United States and the United Kingdom, as well as ongoing collaborations with global regulatory authorities.

Revenue for Stoke Therapeutics is generated through the development and commercialization of its RNA-based medicines. The company's primary products include STK-001, an ASO designed to upregulate Nav1.1 protein expression, and STK-002, an ASO designed to upregulate OPA1 protein expression for the treatment of autosomal dominant optic atrophy (ADOA). These products cater to a niche market, with patients experiencing Dravet syndrome and ADOA, as well as their families and healthcare providers forming the core customer base.

Within the industry, Stoke Therapeutics holds a competitive edge due to its proprietary TANGO platform, which offers several key advantages. These advantages include the selective boosting of expression only in tissues where the protein is normally expressed, no observed unwanted off-target effects, utility across small and large gene targets and mutations, the ability to control dose level and duration, and simple and scalable manufacturing. Stoke's TANGO platform is highly predictive and enables rapid and systematic identification of those targets that are most likely to have clinical relevance, thereby increasing the probability for clinical success and accelerating the expansion of its emerging pipeline.

Stoke's lead program, STK-001, is currently in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy affecting approximately 6.4 in 100,000 people worldwide. The disease is caused by a pathogenic mutation or deletion of the SCN1A gene in approximately 85% of patients, and STK-001 has shown promising results in preclinical studies, including a significant reduction in premature mortality and seizure frequency in a mouse model of Dravet syndrome. End-of-study data from two Phase 1/2a open-label studies of STK-001 demonstrated a significant reduction in convulsive seizure frequency and a durable effect over 12 months. The company plans to meet with regulatory authorities to discuss late-stage clinical development of STK-001.

In addition to STK-001, Stoke is also developing STK-002, a proprietary ASO in preclinical development for the treatment of ADOA, the most common inherited optic nerve disorder. The company has received authorization in the United Kingdom to proceed with a Phase 1 open-label study (OSPREY) of STK-002, which is expected to start in 2024.